

# Resource Summary Report

Generated by [dkNET](#) on Aug 27, 2026

## Raji

RRID:CVCL\_0511

Type: Cell Line

### Proper Citation

RRID:CVCL\_0511

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0511](https://web.expasy.org/cellosaurus/CVCL_0511)

**Proper Citation:** RRID:CVCL\_0511

**Description:** Cell line Raji is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** EBV-related Burkitt lymphoma

**Defining Citation:** [PMID:168255](#), [PMID:170370](#), [PMID:216485](#), [PMID:1086134](#), [PMID:1325212](#), [PMID:1915267](#), [PMID:2140233](#), [PMID:2470097](#), [PMID:2985879](#), [PMID:2998993](#), [PMID:3026973](#), [PMID:3034807](#), [PMID:3080238](#), [PMID:3100061](#), [PMID:3159941](#), [PMID:3518877](#), [PMID:3874327](#), [PMID:3905596](#), [PMID:4122458](#), [PMID:4169243](#), [PMID:4321017](#), [PMID:4321974](#), [PMID:4325933](#), [PMID:4347031](#), [PMID:4364259](#), [PMID:4366935](#), [PMID:4550511](#), [PMID:4736620](#), [PMID:4894370](#), [PMID:5260617](#), [PMID:6018567](#), [PMID:6231253](#), [PMID:6265077](#), [PMID:6286763](#), [PMID:6306472](#), [PMID:6419122](#), [PMID:6500159](#), [PMID:6547209](#), [PMID:6582512](#), [PMID:6592381](#), [PMID:6600440](#), [PMID:6806672](#), [PMID:6954533](#), [PMID:7060222](#), [PMID:7316467](#), [PMID:7849311](#), [PMID:8176200](#), [PMID:8316623](#), [PMID:8344493](#), [PMID:8515068](#), [PMID:8547074](#), [PMID:8558913](#), [PMID:8568269](#), [PMID:8847894](#), [PMID:9192833](#), [PMID:9473234](#), [PMID:9510473](#), [PMID:9685479](#), [PMID:9737686](#), [PMID:9738977](#), [PMID:9787181](#), [PMID:9973220](#), [PMID:10739008](#), [PMID:11226526](#), [PMID:11416159](#), [PMID:12145705](#), [PMID:12967475](#), [PMID:14086209](#), [PMID:14982850](#), [PMID:15028022](#), [PMID:15457187](#), [PMID:15901131](#), [PMID:18357372](#), [PMID:19358282](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:22460905](#), [PMID:22885699](#), [PMID:24590883](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25753668](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:27397505](#), [PMID:27566572](#), [PMID:28196595](#), [PMID:29892436](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

**Comments:** Virology: Contains 50-60 integrated copies of the EBV genome. One copy is integrated in intron 1 of the BACH2 gene (PubMed=14982850)., Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572)., Population: African; Nigerian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** Raji

**Synonyms:** RAJI, P1-Raji, GM04671

**Cross References:** BTO:BTO\_0001154, CLO:CLO\_0008734, CLO:CLO\_0019014, CLO:CLO\_0050995, EFO:EFO\_0002324, MCCL:MCC:0000409, CLDB:cl4086, CLDB:cl4088, CLDB:cl4089, CLDB:cl4090, CLDB:cl4091, CLDB:cl4092, CLDB:cl4990, Abcam:ab271145, Abcam:ab275473, AddexBio:C0003009/4668, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CCL-86, ATCC:CRL-7936, BCRC:60116, BCRJ:0211, BEI\_Resources:ARP-9944, BioGRID\_ORCS\_Cell\_line:272, BioSample:SAMN01821589, BioSample:SAMN01821656, BioSample:SAMN01821715, BioSample:SAMN01821738, BioSample:SAMN03473128, BioSample:SAMN10987653, cancercellines:CVCL\_0511, CCRID:1101HUM-PUMC000046, CCRID:1102HUM-NIFDC00025, CCRID:3101HUMTCHu44, CCRID:4201HUM-CCTCC00191, CCTCC:GDC0191, Cell\_Model\_Passport:SIDM00844, CGH-DB:9204-4, ChEMBL-Cells:ChEMBL3307663, ChEMBL-Targets:ChEMBL614628, CLS:300359, Coriell:GM04671, Cosmic:687850, Cosmic:850211, Cosmic:850387, Cosmic:851997, Cosmic:909262, Cosmic:919136, Cosmic:929816, Cosmic:931110, Cosmic:932761, Cosmic:991549, Cosmic:998718, Cosmic:1019313, Cosmic:1037703, Cosmic:1070707, Cosmic:1071883, Cosmic:1082517, Cosmic:1093788, Cosmic:1107179, Cosmic:1127266, Cosmic:1176615, Cosmic:1191688, Cosmic:1483367, Cosmic:1517664, Cosmic:1818346, Cosmic:2301566, Cosmic:2361386, Cosmic:2649241, Cosmic:2814541, Cosmic:2815215, Cosmic:2823074, Cosmic-CLP:909262, DepMap:ACH-000654, DSMZ:ACC-319, DSMZCellDive:ACC-319, ECACC:85011429, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS260AAA, FANTOM5\_SSTAR:10476-106I8, GDSC:909262, GEO:GSM33154, GEO:GSM99387, GEO:GSM887523, GEO:GSM888605, GEO:GSM1374840, GEO:GSM1374841, GEO:GSM1374842, GEO:GSM1602232, GEO:GSM1602233, GEO:GSM1602234, GEO:GSM1602235, GEO:GSM1602236, GEO:GSM1602237, GEO:GSM1602238, GEO:GSM1602241, GEO:GSM1602242, GEO:GSM1602243, GEO:GSM1602244, GEO:GSM1670357, GEO:GSM3150253, IARC\_TP53:704, IARC\_TP53:21706, ICLC:HTL00002, IGRhCellID:Raji, IHW:IHW04994, IPD-IMGT/HLA:11295, IZSLER:BS TCL 54, JCRB:IFO50046, JCRB:JCRB9012, LiGeA:CCLE\_651, LINCS\_LDP:LCL-2025, Lonza:726, NCBI\_Iran:C127, PharmacDB:Raji\_1282\_2019, PRIDE:PXD005704, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL\_0511, PubChem\_Cell\_line:CVCL\_0511, RCB:RCB1647, RCB:RCB3673, TKG:TKG 0371, TOKU-E:2967, Wikidata:Q4215980

**ID:** CVCL\_0511

**Record Creation Time:** 20220427T221449+0000

**Record Last Update:** 20260815T235614+0000

---

## Ratings and Alerts

No rating or validation information has been found for Raji.

**Warning:** Discontinued: ATCC; CRL-7936

Virology: Contains 50-60 integrated copies of the EBV genome. One copy is integrated in intron 1 of the BACH2 gene (PubMed=14982850)., Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572)., Population: African; Nigerian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 1122 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Zhang H, et al. (2026) A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRP??-Independent Mechanism. Molecular cancer therapeutics, 25(1), 21.

Zhao R, et al. (2026) T cell polarization and NFAT activation are stiffness dependent and differentially regulated by the channels PIEZO1 and ORAI1. Science signaling, 19(922), eadt9566.

Wang L, et al. (2026) A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. Journal of hematology & oncology, 19(1).

Garc??a-Vicente R, et al. (2026) The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(2), 375.

Cai J, et al. (2026) LM-101, an Anti-SIRP?? Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(12), 2391.

- Philbrook P, et al. (2026) Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. *Cancer immunology research*, 14(4), 640.
- Komura S, et al. (2026) Expression of Glycoprotein B (gB) Correlates With Poor Prognosis in Nasopharyngeal Carcinoma. *Cancer science*, 117(5), 1481.
- Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. *Cell reports. Medicine*, 7(2), 102618.
- Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).
- Tripathi C, et al. (2026) Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity. *Cancer research communications*, 6(3), 528.
- Shao N, et al. (2026) A high-throughput modular microfluidic platform for versatile functional assays at single-cell level. *Microsystems & nanoengineering*, 12(1).
- Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. *Cell reports*, 45(1), 116796.
- Ko N, et al. (2026) Optimizing Zirconium-89 labeling for chimeric antigen receptor T cell PET imaging by comparing desferrioxamine and oxine. *Scientific reports*, 16(1).
- Beke F, et al. (2026) L-type voltage-gated Ca<sup>2+</sup> channels control T cell killing via non-canonical Hedgehog signalling. *EMBO reports*, 27(13), 3689.
- Zdanowicz A, et al. (2025) Low-Dose Salinomycin Alters Mitochondrial Function and Reprograms Global Metabolism in Burkitt Lymphoma. *International journal of molecular sciences*, 26(11).
- Shen Y, et al. (2025) Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e09103.
- Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. *Cell reports. Medicine*, 6(10), 102409.
- Maso L, et al. (2025) Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy. *Nature communications*, 16(1), 11264.
- Liu S, et al. (2025) Kaposi's sarcoma-associated herpesvirus (KSHV) gB dictates a low-pH endocytotic entry pathway as revealed by a dual-fluorescent virus system and a rhesus monkey rhadinovirus expressing KSHV gB. *PLoS pathogens*, 21(1), e1012846.
- Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. *Cancer research communications*, 5(3), 527.